Deleuran M, Thaçi D, Beck LA, et al. - Researchers conducted this ongoing, multicenter, open-label extension study to evaluate long-term safety and effectiveness of dupilumab in atopic dermatitis (AD) patients. They assessed long-term dupilumab treatment in adults who had previously partaken in phase 1–3 dupilumab clinical trials in AD. This investigation studied patients given 300 mg dupilumab weekly for up to 76 weeks at data cutoff (April 2016). This study's safety and effectiveness profile support dupilumab's role as a continuous long-term treatment for patients with moderate to severe AD. Sustained improvement in all efficacy outcomes, including skin inflammation, pruritus, and quality of life, has been observed up to 76 weeks. Nasopharyngitis, conjunctivitis, and injection-site reactions were common adverse events included.